RxDoctor Payments DataLook up a doctor →

Nilesh Goswami, MD

Interventional Cardiology · Waco, TXNPI 1467534701

Payments from drug & device makers

$540,301in general payments, 2019–2025

Across 710 payments — averaging $760.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$277K
  • Abbott$104K
  • Angiodynamics, Inc.$42K
  • Medtronic$40K
  • Shockwave Medical, Inc$35K
  • Livanova USA, Inc.$13K
  • plus $29K from 31 others

What the payments were for

  • Consulting fees$7,57512%
  • Speaking & faculty fees$27,70644%
  • Grants$890%
  • Travel & lodging$7,40612%
  • Food & beverage$19,46231%
  • Education$810%
  • Gifts$420%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$540,301 in reported general payments places this provider in the 90th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$98,809
Medicare patients
305
Services billed
870

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban147$114,230
EntrestoSacubitril/Valsartan34$29,840
Repatha SureclickEvolocumab27$19,423
FarxigaDapagliflozin Propanediol18$15,002
JardianceEmpagliflozin16$13,613
BrilintaTicagrelor12$9,487
Metoprolol Succinate399$5,693
ClopidogrelClopidogrel Bisulfate196$2,226
Ezetimibe71$2,220
Rosuvastatin Calcium104$2,185
Atorvastatin Calcium149$1,616
Lisinopril107$1,192
Spironolactone103$815
Carvedilol73$750
Valsartan23$597

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$188$114,230147 claims
NovartisEntresto$238$29,84034 claims
AstraZenecaFarxiga, Brilinta$214$24,48930 claims
Boehringer IngelheimJardiance$131$13,61316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Waco

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →